1. Home
  2. Knowledge Base
  3. References
  4. Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Knuplez E, Krier-Burris R, Cao Y, Marsche G, O’Sullivan J, Bochner BS (2020) Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls. J Leukoc Biol 108:43-58. doi: 10.1002/jlb.3hi0120-381r

Objective: To determine if targeting Siglec-8 with mouse IgG1 antibodies, rather than targeting Siglec-F with rat IgG antibodies, in mice transgenic for Siglec-8, will prove to be a more effective strategy for eliminating mouse eosinophils in vivo.

Summary: This study is the first to describe a novel mouse strain of Siglec-8+F− eosinophils—a useful tool for studying human Siglec biology in preclinical models.

Usage: Siglec-8+F− mouse eosinophils were pretreated with 10 μg/mL saporin-conjugated isotype controls (mouse IgG1 or rat IgG2), anti-Siglec-8 (2C4) or anti-Siglec-F (9C7) antibodies for 24 h.

Related Products: Custom Conjugates